spacer
home > pmps > winter 2017 > formulating a plan
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Formulating a Plan

High doses are often necessary to deliver enough of an orally administered drug to the lungs or nasal passages through the bloodstream. As many medicines are now highly potent, delivery by mouth has the potential to cause severe side effects. Combined with this, when products are taken in this way they are easily metabolised, which means that they are not always adequately administered to the nose or lungs, thus limiting the success of the treatment.

In contrast, inhalation formulations enable pharmaceuticals to be delivered directly to the nasal passages or lungs in smaller doses, reducing the risks of both side effects and drug-to-drug interaction. Their growth in popularity can further be attributed to their ability to give the most direct access to a drug target. For example, many inhaled products are steroid drug classes. They can have a harmful impact on growth and hormone balance if taken in large amounts by children and is, therefore, beneficial to deliver a smaller dose to the site of action.

These local therapies offer fast absorption, rapid response and enable a drug to be administered straight to the conducting zone of the lungs. As a result, they work particularly well for conditions such as asthma. Inhalation also represents a very attractive way to deliver drugs to the brain. In the treatment of migraines, for instance, nasal spray drug delivery into the nose can bring fast and effective relief.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Poonam Aliyah Sheth is a Research Scientist specialising in inhalation product development at Recipharm and she holds a PhD in Pharmaceutical Science from the University of Arizona, US. With particular expertise in MDI formulations, dry powder inhalers and nebulised formulations, she has been integral to the development and manufacture of many original and generic products for inhalation drug delivery for global clients, ranging from emerging to large pharmaceutical organisations.

Ramil Menzeleev, PhD, is Director of Recipharm’s Analytical Sciences department. He oversees analytical method development, providing scientific review for client projects while also participating in the design and development of electronic data recording software platforms. A specialist in analytical chemistry, his expertise covers fast, highly sensitive, accurate and high-throughput quantitation method development. He also manages the selection and implementation of IT solutions, including software for business process management, as well as review and approval software for design, validation, implementation and use in Good Manufacturing Practice environments.
spacer
Poonam Aliyah Sheth
spacer
spacer
spacer
Ramil Menzeleev
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its steady growth.

According to the data obtained by WACD, the international air cargo information provider, in May; Turkish Cargo, the global air cargo brand providing service to 124 countries around the world, increased its tonnage rate by 7.1 percent, and grew substantially across the industry which shrank by 5.1 percent in the global air cargo market.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement